Cost-effectiveness of GeneXpert Omni compared with GeneXpert MTB/Rif for point-of-care diagnosis of tuberculosis in a low-resource, high-burden setting in Eastern Uganda: a cost-effectiveness analysis based on decision analytical modelling

dc.contributor.authorEjalu David Livingstone
dc.contributor.authorIrioko Aaron
dc.contributor.authorKirabo Rhoda
dc.contributor.authorMukose Aggrey David
dc.contributor.authorEkirapa Elizabeth
dc.contributor.authorKagaayi Joseph
dc.date.accessioned2023-07-18T14:45:54Z
dc.date.available2023-07-18T14:45:54Z
dc.date.issued2022-08-08
dc.description.abstractTo determine the cost-effectiveness of Xpert Omni compared with Xpert MTB/Rif for point-of-care diagnosis of tuberculosis among presumptive cases in a low-resource, high burden facility. Cost-effectiveness analysis from the provider’s perspective. Setting A low-resource, high tuberculosis burden district in Eastern Uganda. Participants A provider’s perspective was used, and thus, data were collected from experts in the field of tuberculosis diagnosis purposively selected at the local, subnational and national levels. A decision analysis model was contracted from TreeAge comparing Xpert MTB/Rif and Xpert Omni. Cost estimation was done using the ingredients’ approach. One-way deterministic sensitivity analyses were performed to identify the most influential model parameters. Outcome measure The outcome measure was incremental cost per additional test diagnosed expressed as the incremental cost-effectiveness ratio. The total cost per test for Xpert MTB/Rif was US$14.933. Cartridge and reagent kits contributed to 67% of Xpert MTB/Rif costs. Sample transport costs increased the cost per test of Xpert MTB/Rif by $1.28. The total cost per test for Xpert Omni was $16.153. Cartridge and reagent kits contributed to over 71.2% of Xpert Omni’s cost per test. The incremental costeffectiveness ratio for using Xpert Omni as a replacement for Xpert MTB/Rif was US$30.73 per additional case detected. There was no dominance noted in the cost-effectiveness analysis, meaning no strategy was dominant over the other. The use of Xpert Omni at the point-of-care health facility was more effective but with an increased cost compared with Xpert MTB/Rif at the centralised referral testing facility.en_US
dc.identifier.doihttps://doi.org/10.1136/bmjopen-2021-059823
dc.identifier.issnOnline ISSN: 2044-6055
dc.identifier.issnPrint ISSN: 2044-6055
dc.identifier.urihttp://hdl.handle.net/20.500.12280/3036
dc.language.isoenen_US
dc.publisherBMJen_US
dc.relation.ispartofseriesBMJ Open;2022;12:e059823
dc.titleCost-effectiveness of GeneXpert Omni compared with GeneXpert MTB/Rif for point-of-care diagnosis of tuberculosis in a low-resource, high-burden setting in Eastern Uganda: a cost-effectiveness analysis based on decision analytical modellingen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Ejalu-Health-Article-2022-Cost-effectiveness.pdf
Size:
1.13 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: